We break down why "just a shampoo" is never the answer for dog hair loss and what the real path to a healthy coat involves ...

Assistant Professor of Oncology Division of Pediatric Oncology Department of Immunology Department of Radiology Roswell Park Comprehensive Cancer Center Assistant Clinical Professor Department of ...

In an experiment using mice, Japanese researchers reported success in targeting and shrinking cancer cells with natural bacteria, a development they said will pave the way for new treatments.

Remarkably, the combination of atorvastatin with anti-PD-1 therapy reduced tumor weight by nearly half (45%), while the combination with lenvatinib led to a 58% reduction. "This approach could be a ...

When Nat Myers first went into the hospital back in February, he said he thought he was dealing with some type of lung infection. It turned out to be something far more sinister, and the 33-year-old ...

New research from Memorial Sloan Kettering Cancer Center (MSK) shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental ...

First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex Bluejay Therapeutics has enrolled the first patient in AZURE-2, a global phase 3 clinical trial evaluating brelovitug (BJT-778 ...

The FDA approved Monjuvi with Revlimid and Rituxan for follicular lymphoma, the same combination that brought survivor Troy Anderson a lasting response. The U.S. Food and Drug Administration approved ...

TUESDAY, Oct. 8, 2024 (HealthDay News) -- A recently approved targeted chemotherapy drug can significantly extend the lives of advanced breast cancer patients who have developed tumors in their brains ...

RYBREVANT ® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment "Choosing the first treatment for EGFR-mutated NSCLC ...

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year ...